Combination of cinacalcet, calcitriol, and lanthanum carbonate in treatment of secondary hyperparathyroidism in uremia under hemodialysis
Journal Title: Chinese Journal of Clinical Research - Year 2024, Vol 37, Issue 9
Abstract
Objective To observe the efficacy of combined treatment with cinacalcet, calcitriol, and lanthanum carbonate in uremia patients undergoing hemodialysis (HD) with secondary hyperparathyroidism (SHPT). Methods From January 2020 to December 2022, 80 uremia patients under HD with SHPT treated at Huangshan City People's Hospital were selected. They were randomly divided into the control group (40 cases, treated with calcitriol) and the study group (40 cases, treated with a combination of cinacalcet, calcitriol, and lanthanum carbonate). The calcium-phosphorus product, intact parathyroid hormone (iPTH), parathyroid volume, and carotid intima-media thickness (IMT), as well as adverse reactions, were compared between the two groups. Results Compared with before treatment, both groups showed a decrease in calcium-phosphorus product and iPTH after 1, 3, and 6 months of treatment (P＜0.05). Moreover, compared with the control group, the study group had lower calcium-phosphorus product and iPTH after 1, 3, and 6 months of treatment (P＜0.05). Compared with before treatment, both groups showed a reduction in parathyroid volume after 1, 3, and 6 months of treatment (P＜0.05). The study group also showed a reduction in carotid IMT after 3 and 6 months of treatment (P＜0.05), while the control group showed a reduction in IMT after 6 months of treatment (P＜0.05). Furthermore, compared with the control group, the study group had lower parathyroid volume and IMT after 3 and 6 months of treatment (P＜0.05). The incidence of adverse reactions in the study group was 17.50%, which was not significantly different from the 15.00% in the control group (χ2=0.092, P=0.762). Conclusion For uremia patients under HD accompanied by SHPT, combined treatment of cinacalcet, calcitriol, and lanthanum carbonate can improve calcium and phosphorus metabolism, regulate iPTH, reduce parathyroid volume and the risk of carotid atherosclerosis, without increasing adverse reactions.
Authors and Affiliations
WANG Chengjun , WANG Hong, WAN Jiakui, SHAO Jue
Keywords
Related Articles
- EP ID EP745465
- DOI 10.13429/j.cnki.cjcr.2024.09.018
- Views 33
- Downloads 0
Ketamine: from narcotic analgesics to antidepressants
Ketamine compound was firstly synthesized for more than 60 years. It is widely used in clinical anesthesia due to its potent analgesic effect and lower deleterious impacts on circulatory and respiratory functions. Very r...
Protective effect of esketamine on hepatic ischemia-reperfusion injury
Esketamine, as a perioperative sedative and analgesic drug, has been widely used in Europe and America. However, the protective effect of esketamine on the liver during the perioperative period is still in the applicated...
Correlation study between insulin resistance index and non-alcoholic fatty liver disease
Objective To explore the relationship between homeostasis model assessment of insulin resistance index (HOMA-IR) and non-alcoholic fatty liver disease (NAFLD). Methods The registered participants aged 18 years or older i...
Association of skeletal muscle mass index with non-traumatic rotator cuff tear in patients with type 2 diabetes mellitus
"<b>Objective</b> To investigate the relationship between skeletal muscle mass index (SMI) and non-traumatic rotator cuff tear(RCT) in patients with type 2 diabetes mellitus (T2DM). <b>Methods</b> The clinical data of...
Efficacy and safety of argatroban combined with plasmin in the treatment of acute cerebral infarction
Objective To observe the effects of combined application of argatroban and plasmin on the degree of neurological function deficit and neutrophil (NEUT) count in patients with acute cerebral infarction (ACI) and their sa...